Des the proposed medicine address a relevant public health need? Does the proposed medicine address a relevant public health need? Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? The WYes Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? Does adequate evidence in the edicine for the efficacy/effectiveness of the medicine for the review process) Does adequate evidence in the edicine for the efficacy/effectiveness of the medicine for the proposed indication? Does adequate evidence in the edicine for the efficacy of form of the effectiveness of the medicine for the proposed indication? A Cochrane review of the effectiveness of the medicine for the proposed indication? Does adequate evidence included in the application, and/or additional evidence in the effectiveness of the medicine for the proposed indication? Does adequate evidence included in the application, and/or additional evidence identified during the review process) Does adequate evidence included in the application, and/or additional evidence identified during the review process) Does adequate evidence included in the application, and/or additional evidence included in the application of form the effectiveness of the medicine for the proposed indication? The Education of mortality is a proper form of the effectiveness of the medicine for the proposed indication? Does adequate evidence included in the application, and/or additional evidence included in the application, and/or additional evidence included in the application, and/or additional evidence included in the application of form the effect of t	Not recommended Justification: Tocilizumab is a monoclonal antibody that acts as an IL-6 receptor antagonist. It is approved for intravenous use in rheumatoid arthritis. The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilates. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. No Not applicable Not No No Not applicable Not No No No Not No No
Justification: Tocilizumab is a monoclonal antibody that acts as an IL-6 receptor antagonist. It is approved for intravenous use in rheumatoid arthritis. The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does abequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? Not applicable. Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Sy Yes No Not applicable comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe diseases. There was greate benefit in patients receiving steroids.	Justification: Tocilizumab is a monoclonal antibody that acts as an It-6 receptor antagonist. It is approved for intravenous use in rheumatoid arthritis. The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the It-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of It-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? No
Tocilizumab is a monoclonal antibody that acts as an IL-6 receptor antagonist. It is approved for intravenous use in rheumatoid arthritis. The 2022 WHOC Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHOl living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? Syes No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Syes No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Syes Wes No Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe diesaes. There was greater benefit in patients receiving steroids. A Cochrane review confir	Tocilizumab is a monoclonal antibody that acts as an IL-6 receptor antagonist. It is approved for intravenous use in rheumatoid arthritis. The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GOG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Yes No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths.
approved for intravenous use in rheumatoid arthritis. The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Extra the proposed indication? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Extra the proposed indication? No Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving ste	approved for intravenous use in rheumatoid arthritis. The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Syes No Not applicable Not applicable Not applicable Not applicable Not application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? We yes No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Wes No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Poes adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? Wes No Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. ■ Yes ■ No ■ Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. ■ Yes ■ No ■ Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. ■ Yes ■ No ■ Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction of mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? No No No applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. X Yes No No No modication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. □ No □ Not applicable □ Comments: □ There have been an estimated 600 million cases of Covid-19 with 6 million deaths. □ No □ Not applicable □ Comments: □ The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	compared to standard care or placebo. The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? No No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. ■ Yes □ No □ Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. ■ Yes □ No □ Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. ■ No □ Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) No Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	blockers in patients with severe and critical Covid-19 disease. Does the proposed medicine address a relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) No Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) No No Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	relevant public health need? No Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) No No Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
□ Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	□ Not applicable Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) □ Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	Comments: There have been an estimated 600 million cases of Covid-19 with 6 million deaths. Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) Comments: □ No □ Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) There have been an estimated 600 million cases of Covid-19 with 6 million deaths. ✓ Yes □ No □ No □ Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) No □ Not applicable Comments: The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
(this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	(this may be evidence included in the application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	application, and/or additional evidence identified during the review process) The 2022 WHO Covid-19 living guideline noted that there was high level evidence of a reduction of mortality based on 27 studies including 10,930 patients. There were an
reduction of mortality based on 27 studies including 10,930 patients. There were an estimated 16/1000 fewer deaths in the IL-6 blocker group. There was also high-level evidence for a reduction in the need for mechanical ventilation. Sub-group analysis noted no modification of effect based on whether the patient had critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	reduction of mortality based on 27 studies including 10,930 patients. There were an
critical or severe disease. There was greater benefit in patients receiving steroids. A Cochrane review confirmed that tocilizumab reduced all cause day 28 mortality	
compared to standard care or placebo.	

24^{th} WHO Expert Committee on Selection and Use of Essential Medicines Expert review

Does adequate evidence exist for the safety/harms associated with the proposed medicine? (this may be evidence included in the application, and/or additional evidence identified during the review process) Are there any adverse effects of concern, or that may require special monitoring?	 ✓ Yes ☐ No ☐ Not applicable Comments: The GDG noted high uncertainty about the effect of tocilizumab on adverse events. The Cochrane review also noted similar uncertainty but concluded that there were probably fewer serious adverse events than placebo. ☐ Yes ☒ No ☐ Not applicable Comments:
Are there any special requirements for the safe, effective and appropriate use of the medicines? (e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)	☐ Yes ☑ No ☐ Not applicable Comments: None of the trials enrolled children or pregnant women.
Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?	 ✓ Yes ☐ No ☐ Not applicable Comments: The drug has been made available through the ACT-Accelerator platform. The ICER for combination therapy for tocilizumab with dexamethasone compared to dexamethasone alone was between around \$16-26,000 dollars in the higher and lower mortality scenarios.
Are there any issues regarding the registration of the medicine by national regulatory authorities? (e.g. accelerated approval, lack of regulatory approval, off-label indication)	☐ Yes ☑ No ☐ Not applicable Comments: Tocilizumab is not part of the MPP initiative.

24^{th} WHO Expert Committee on Selection and Use of Essential Medicines Expert review

Is the proposed medicine	⊠ Yes
recommended for use in a current WHO guideline?	□ No
(refer to:	☐ Not applicable
https://www.who.int/publications/who-	Comments:
guidelines)	The WHO living guideline has a strong recommendation for the use of IL-6 receptor blockers in patients with severe and critical Covid-19 disease. This included tocilizumab and sarilumab.